Juan José
Alegre Sancho
Publicaciones en las que colabora con Juan José Alegre Sancho (11)
2022
-
Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting
Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573
2020
-
A cross-disease meta-GWAS identifies four new susceptibility loci shared between systemic sclerosis and Crohn’s disease
Scientific Reports, Vol. 10, Núm. 1
2019
-
Evaluation of 12 GWAS-drawn SNPs as biomarkers of rheumatoid arthritis response to TNF inhibitors. A potential SNP association with response to etanercept
PLoS ONE, Vol. 14, Núm. 2
-
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
Nature Communications, Vol. 10, Núm. 1
2018
-
Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis
PLoS ONE, Vol. 13, Núm. 5
2016
-
Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies
Arthritis and Rheumatology, Vol. 68, Núm. 9, pp. 2338-2344
-
LILRA3 deficiency is not involved in the giant cell arteritis and systemic sclerosis predisposition
Clinical and Experimental Rheumatology
-
Replication of PTPRC as genetic biomarker of response to TNF inhibitors in patients with rheumatoid arthritis
Pharmacogenomics Journal, Vol. 16, Núm. 2, pp. 137-140
2015
-
Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis
Clinical and Experimental Rheumatology, Vol. 33, pp. 31-35
-
Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study
Arthritis Research and Therapy, Vol. 17, Núm. 1
2014
-
A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility
Arthritis Research and Therapy, Vol. 16, Núm. 1